Search | Clinical Trials Finder

Conditions: Cytomegalovirus Infections
Interventions: MF-59, Placebo, CMV gB vaccine; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 17 Years · Female only
Enrollment: 409 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 5
States / cities: Cincinnati, Ohio • Nashville, Tennessee • Galveston, Texas + 1 more

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska

Conditions: Influenza, Human
Interventions: aQIV, Comparator QIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 2,044 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 12
States / cities: Mobile, Alabama • Tempe, Arizona • Atlantis, Florida + 9 more

Conditions: A/Vietnam/H5N1 Influenza Virus
Interventions: 7.5 mcg H5N1 (stored as monobulk), 15 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored as monobulk), 90 mcg H5N1 (stored in vials), MF59, MF59 (stored as monobulk); Biological · Other
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 6
States / cities: Atlanta, Georgia • Council Bluffs, Iowa • Lenexa, Kansas + 3 more

Conditions: Influenza, Human
Interventions: Experimental: IIV-A Investigational IIV-A administered as a single dose intramuscularly on Day 1, Experimental: aIIV-B Investigational aIIV-B administered as a single dose intramuscularly on Day 1, Experimental: aIIV-C Investigational aIIV-C administered as a single dose intramuscularly on Day 1, Active Comparator: Licensed IIV IIV administered as a single dose intramuscularly on Day 1; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 47
States / cities: Tempe, Arizona • Huntington Beach, California • San Diego, California + 42 more

Conditions: Influenza
Interventions: MF59-eH1N1; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 3 Years to 8 Years
Enrollment: 1,357 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 34
States / cities: Downey, California • Madera, California • Paramount, California + 29 more

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Influenza, Human
Interventions: Investigational aQIVc, licensed QIVr, licensed aQIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 7,741 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 51
States / cities: Tempe, Arizona • Little Rock, Arkansas • Huntington Beach, California + 47 more

Conditions: Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4); Biological
Lead sponsor: Kaiser Permanente; Other
Eligibility: 65 Years and older
Enrollment: 1,500,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza, Human
Interventions: aQIV or aTIV, QIV or TIV; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 65 Years and older
Enrollment: 38,769 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 111
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more

Conditions: Influenza
Interventions: Influenza A/H9N2 vaccine, MF59 adjuvant; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 34 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: ALVAC-HIV (vCP2438), Bivalent subtype C gp120/MF59, Bivalent subtype C gp120/AS01(B), Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Decatur, Georgia • Boston, Massachusetts + 5 more

Conditions: Influenza A Virus, H5N1 Subtype
Interventions: VN, IN, dk/BANG, gf/WA, bhg/QL, AS03 adjuvant, MF59 adjuvant; Biological
Lead sponsor: Biomedical Advanced Research and Development Authority; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 720 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: San Diego, California • Peoria, Illinois • Lenexa, Kansas + 3 more

Conditions: Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions: aH5N8c on Day 1, aH5N6c on Day 1, aH5N8c on Day 22, aH5N6c on Day 22, aH5N8c on Day 202; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 18 Years and older
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1MN, rgp120/HIV-1 SF-2; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 16 Years to 60 Years
Enrollment: 296 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1997
U.S. locations: 7
States / cities: Birmingham, Alabama • St Louis, Missouri • Rochester, New York + 3 more

Conditions: Influenza
Interventions: Aluminum hydroxide, Inactivated Influenza A/H5N1 Vaccine (Chiron), MF-59, Placebo; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 394 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 4
States / cities: Stanford, California • St Louis, Missouri • Cincinnati, Ohio + 1 more

Conditions: HIV Infections
Interventions: Sub C gp140 Vaccine, MF59C.1 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Birmingham, Alabama • Nashville, Tennessee • Seattle, Washington

Conditions: HIV Infections
Interventions: Clade B gag DNA/PLG and env DNA/PLG Microparticles, Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 4
States / cities: St Louis, Missouri • Providence, Rhode Island • Nashville, Tennessee + 1 more

Conditions: Avian Influenza
Interventions: MF59, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years to 99 Years
Enrollment: 479 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 10
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more

Conditions: Influenza, Human
Interventions: Investigational aIIV4c, IIV4c, aIIV4, RIV4; Biological
Lead sponsor: Seqirus; Industry
Eligibility: 50 Years and older
Enrollment: 471 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Mobile, Alabama • Tempe, Arizona • Jacksonville, Florida + 17 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2, MTP-PE/MF59; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 4
States / cities: St Louis, Missouri • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Avian Influenza
Interventions: AS03, MF59, Monovalent Influenza A/H5N8 vaccine; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 388 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 7
States / cities: Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 4 more

Conditions: HIV Infections, HIV Seronegativity
Interventions: MTP-PE/MF59, Env 2-3; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1992
U.S. locations: 3
States / cities: Rochester, New York • Nashville, Tennessee • Seattle, Washington

Conditions: Healthy
Interventions: IVX-121, IVX-241, Placebo, MF59®; Biological · Other
Lead sponsor: Icosavax, Inc.; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Hollywood, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more

Search by objective public record fields.

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years)

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age

Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59

Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults

A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults

H5 Adult - Chiron Study of Bird Flu Vaccine

Evaluating the Safety and Immune Response to an HIV Vaccine in Healthy, HIV-Uninfected Adults Who Have Participated in Previous HIV Vaccine Clinical Trials and in Adults Who Have Not Participated in Previous HIV Vaccine Clinical Trials

Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults

H7N9 Mix and Match With MF59 in Healthy Elderly Persons

Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults

Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant

H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Safety and Immunogenicity of IVX-A12 in Healthy Older Adults